To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.

This was a multi-center open label study to provide continued supply of QTI571 to patients in Japan who were treated in the extension study (A2301E1) and were judged by the investigator to benefit from continued QTI571 treatment.

Inclusion Criteria:

• patient is receiving QTI571 for the treatment of Pulmonary Arterial Hypertension (PAH) and is currectly enrolled in a long-term extension study (CQTI571A2301E1) in Japan.
• Patient is currently benifitting form the treatment with QTI571 in the opinion of the investigator.

Exclusion Criteria:

• Patient has been permanently discontinued from QTI571 study treatment in the parent study.
• Concomitant use of oral vitamin K antagonist medication.

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Adverse events were collected up to approximately 2.9 years

AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 2.9 years. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 2.9 years

No efficacy data was captured in this study, and no analysis of efficacy was planned. No formal analyses of Adverse Events were undertaken.